BTIG analyst Marie Thibault has maintained their bullish stance on BSX stock, giving a Buy rating today.
Marie Thibault’s rating is based on Boston Scientific’s strong financial performance and promising outlook. The company reported impressive first-quarter revenue and earnings per share, surpassing both its own guidance and market expectations. Key contributors to this success were higher-than-expected sales in electrophysiology and interventional cardiology, particularly from the Farapulse franchise, which has positioned Boston Scientific as a leading player in the electrophysiology market.
Furthermore, the company demonstrated effective cost management, achieving better-than-expected margins despite facing tariff impacts. Boston Scientific’s management has also raised its guidance for 2025, indicating confidence in sustained revenue growth and profitability. The upcoming transition in the CFO position is expected to be smooth, maintaining stability in leadership. These factors collectively support the Buy rating, with an increased price target reflecting the company’s robust growth potential.
In another report released today, TD Cowen also reiterated a Buy rating on the stock with a $115.00 price target.
Based on the recent corporate insider activity of 131 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.